Introduction
============

Colorectal cancer (CRC) is a type of malignant tumor developed in the rectum or colon, and it is estimated that there are currently \>1 million people who are living with CRC in the USA ([@b1-ol-0-0-3956]). It is the second leading cause of cancer-associated mortalities among all cancer types that affect both females and males ([@b2-ol-0-0-3956]). An association has been identified between CRC and a relatively high 5-year survival rate at early stages of the disease, while the survival is poor when distant and nodal metastasis is exhibited ([@b3-ol-0-0-3956],[@b4-ol-0-0-3956]). The number of patients with metastatic status is up to 30%, and these patients present a 5-year survival rate of \<10% ([@b5-ol-0-0-3956],[@b6-ol-0-0-3956]). In China, the mortality associated with CRC increased by 17.9% between 1973--1975 and 2004--2005 ([@b7-ol-0-0-3956]). Thus, it is of great importance to identify the genetic changes and potential underlying mechanisms in CRC.

Genes involved in the metastasis process in CRC have been extensively studied. Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations have been reported to be a predictor of resistance to the monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) in metastatic CRC ([@b8-ol-0-0-3956]). In addition, B-Raf proto-oncogene, serine/threonine kinase (*BRAF*), and phosphatase and tensin homolog (*PTEN*) mutations are considered to be implications for the targeted treatment in metastatic CRC ([@b9-ol-0-0-3956]). Furthermore, a previous study revealed that the forced expression of chemokine (C-X-C motif) receptor 3 (*CXCR3*) promoted preferential metastasis to draining lymph nodes in CRC, while *CXCR3* knockdown significantly decreased dissemination of cancer cells to the lungs and liver; thus, *CXCR3* may be a potential therapy against metastatic CRC ([@b10-ol-0-0-3956]). The receptor of advanced glycation end products is a prognostic biomarker of CRC metastasis ([@b11-ol-0-0-3956]).

Furthermore, numerous metastasis-associated genes have been screened by gene expression profiling. For instance, Stange *et al* ([@b12-ol-0-0-3956]) used microarray data to identify genes associated with CRC metastasis to the liver. As a result, 163 unique genes were identified to be significantly overexpressed, whereas 15 genes were significantly downregulated ([@b12-ol-0-0-3956]). These genes, including *CYP2E1*, *CYP4A11*, *CRP*, *ORM1*, *SAA1*, *APOA1*, *FGA* and *FGB*, may be associated with metabolism and inflammatory response. Del Rio *et al* ([@b13-ol-0-0-3956]) identified the 33-gene signature to classify the hepatic metastases, primary tumors, normal colon mucosa and normal liver tissues, and indicated that these genes may influence the CRC metastasis to the liver by involving the extracellular matrix remodeling. However, the genes identified in a single dataset may be limited if they have not been confirmed in other datasets.

The present study aimed to use the data of Stange *et al* ([@b12-ol-0-0-3956]) and Del Rio *et al* ([@b13-ol-0-0-3956]) together, to further detect the candidate metastasis-associated genes in CRC. The metaDE package in R language, which implements 12 major meta-analyses in differential expression screening ([@b14-ol-0-0-3956]), was used to screen the differentially expressed genes (DEGs) between primary and metastatic cancer samples in the two datasets. Functional enrichment was also conducted for the significantly associated functions and pathways. By calculating the standard deviations of common DEGs in another dataset with clinical data, candidate metastasis-associated genes were collected, followed by survival analysis.

Materials and methods
=====================

### Microarray data

The Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) database was retrieved for obtaining the microarray data with the following accession numbers: GSE14297 ([@b12-ol-0-0-3956]), GSE49355 ([@b13-ol-0-0-3956],[@b15-ol-0-0-3956]) and GSE29621 ([@b16-ol-0-0-3956]). A total of 18 primary CRC and 18 matched liver metastasis samples were available in the GSE14297 dataset, based on the GPL6370 Illumina human-6 v2.0 expression beadchip (extended). Similarly, the expression data of 20 primary CRC and 19 matched liver metastasis samples in the GSE49335 dataset, based on GPL10430 Rosenstiel *Fundulus heteroclitus* 7K array, were downloaded. In addition, the GSE29621 dataset included 46 primary CRC samples, 18 metastatic samples and 1 sample with unknown metastatic status, based on the platform of GPL570 (HG_U133_Plus_2) Affymetrix Human Genome U133 Plus 2.0 Array.

### Data processing

The gene expression profiles of GSE14297 were prenormalized, while the raw CEL data ([media.affymetrix.com/support/developer/powertools/changelog/gcos-agcc/cel.html](media.affymetrix.com/support/developer/powertools/changelog/gcos-agcc/cel.html)) in GSE49335 and GSE29621 were initially normalized using the robust multi-array average method in R software, version 2.6.0 (R Foundation for Statistical Computing, Vienna, Austria; [www.R-project.org/](www.R-project.org/)). The median value of multiple probes corresponding to a same gene was used as the expression value.

### Microarray meta-analysis for DEGs

Initially, the expression values obtained from the GSE14297 and GSE49335 datasets were used to screen DEGs between primary and metastatic CRC samples. To eliminate discrepancies, the metaDE package in R language ([@b14-ol-0-0-3956]) in R was used as a supplement for Fishers exact test. Next, clustering analysis was performed to detect the distinguishing effect of metaDE on differential expression in different sample groups. The threshold for DEGs was a false discovery rate (FDR) of \<0.05 in metaDE, combined with a P value of \<0.05 in Fisher\'s exact test. P\<0.05 and FDR\<0.05 were considered to indicate a statistically significant difference.

### DEG enrichment analysis

In order to identify the significantly altered functions and pathways during the metastasis of CRC, the online tools in Database for Annotation, Visualization, and Integrated Discovery (DAVID version 6.7; <http://david.abcc.ncifcrf.gov/>) were used for the enrichment analysis. FDR\<0.01 was set as the cut-off value for the enrichment process.

### Metastasis-associated genes in CRC

Fold-changes (increase or decreased) in the expression of the selected genes were investigated, and DEGs with a fold-change of \>2 were considered to be the metastasis-associated genes in CRC. Common metastasis-associated genes were obtained by comparing data in the profiles of GSE14297 and GSE49335. Next, the expression values of these common metastasis-associated genes recorded in GSE29621 were obtained, in order to calculate the standard deviation of common genes in all the 65 samples. Genes with a high standard deviation in their expression were defined as the candidate metastatic genes in CRC.

### Survival analysis

The clinical data of CRC patients were also obtained from the GSE29621 dataset, and were subjected to survival analysis. Using the log-rank test, the effects of metastasis and adjuvant chemotherapy on survival were detected. Additionally, all the 65 samples were divided into the high expression and low expression groups, according to the expression levels of the candidate metastatic genes. Subsequently, the log-rank test was conducted to identify the effect of these candidate genes on the survival of CRC patients.

Results
=======

### Data processing and DEG screening

Initially, the expression profiles were normalized, and the results are shown in [Fig. 1](#f1-ol-0-0-3956){ref-type="fig"}. Using the threshold of FDR\<0.05 in metaDE and P\<0.05 in Fisher\'s exact test, a total of 370 genes were identified to be differentially expressed between the primary and metastatic CRC samples in GSE14297 and GSE49335, among which 153 upregulated and 217 downregulated genes were detected. [Fig. 2](#f2-ol-0-0-3956){ref-type="fig"} shows the number of genes that are differentially expressed against various FDR values. The clustering analysis results indicated that the DEGs selected using metaDE analysis may be able to distinguish metastatic cancer samples from non-metastatic samples ([Fig. 3](#f3-ol-0-0-3956){ref-type="fig"}).

### DEG enrichment analysis

DAVID was applied to investigate the function and pathway enrichment. Upregulated genes were mainly enriched in immune-associated functions, such as repose to wounding and inflammatory response, as well as in metabolic process-associated functions, including peptidase inhibitor activity and carbohydrate binding. Complement and coagulation cascades, and drug metabolism were among the significantly enriched pathways ([Table I](#tI-ol-0-0-3956){ref-type="table"}). Downregulated genes were significantly enriched in the functions of vasculature development, cell adhesion, biological adhesion and extracellular matrix structure; however, no pathways were enriched ([Table II](#tII-ol-0-0-3956){ref-type="table"}).

### Screening of candidate metastasis-associated genes

Following the intersection of DEGs in the GSE49355 and GSE14927 datasets, a total of 77 common DEGs were obtained, consisting of 17 downregulated and 59 upregulated genes. The expression values of these 77 common DEGs in the GSE29621 dataset were used to calculate the standard deviation, and 12 genes with a standard deviation \>1 were identified: carbonic anhydrase II (*CA2*); carcinoembryonic antigen-related cell adhesion molecule 7 (*CEACAM7*); chloride channel accessory 4 (*CLCA4*); *CLCA1*; CXC ligand 14 (*CXCL14*); Fc fragment of immunoglobulin G binding protein (*FCGBP*); immunoglobulin J polypeptide, linker protein for immunoglobulin α and µ polypeptides (*IGJ*); lipocalin 2 (*LCN2*); matrix metallopeptidase 1 (*MMP1*); *MMP3*; peptidase inhibitor 3, skin-derived (*PI3*); and placenta-specific 8 (*PLAC8*). A larger deviation value indicated great changes in the samples; thus, these 12 genes were regarded as candidate metastasis-associated genes, and may exert an intensive effect on the survival of patients.

### Survival analysis

Univariate survival analysis was conducted via the log-rank test. As shown in [Fig. 4](#f4-ol-0-0-3956){ref-type="fig"}, a significantly decreased overall survival time was observed in patients with metastasis (P\<0.05), while the disease-free survival times were not changed according to the metastatic status of the cancer. Furthermore, adjuvant chemotherapy demonstrated no statistically significant effect on the overall and disease-free survival times (P\>0.05). Analysis of the 12 candidate metastasis-associated genes revealed that downregulation of *FCGBP* markedly decreased the patients\' overall survival time (P=0.184); however, no effect was observed on the disease-free survival time ([Fig. 5](#f5-ol-0-0-3956){ref-type="fig"}).

Discussion
==========

At present, metastasis remains an important factor contributing towards the majority of cancer-associated mortalities, as metastatic cancer is often resistant to conventional therapies ([@b17-ol-0-0-3956],[@b18-ol-0-0-3956]). However, reliable and sensitive methods for detecting early metastasis in CRC are not currently available. In the present study, gene expression data were initially analyzed using the metaDE package in R language, in order to identify the DEGs in CRC samples, and a total of 370 genes were identified as DEGs between primary and metastatic cancer samples. In addition, clustering analysis demonstrated the reliability of the identified DEGs. By comparing the expression levels in different datasets, 12 genes were identified among the DEGs as the metastasis-associated genes in CRC, including *CA2*, *CEACAM7*, *CLCA4*, *CLCA1*, *CXCL14*, *FCGBP*, *IGJ*, *LCN2*, *MMP1*, *MMP3*, *PI3* and *PLAC8*. Subsequently, *FCGBP* was demonstrated to influence the patients\' survival.

The carbonic anhydrase family is a set of proteins that are important to the pH regulatory system. Carbonic anhydrase IX (*CA9*) is overexpressed in numerous types of cancer cells, and various agents targeting *CA9* are currently in preclinical or clinical development for cancer therapy ([@b19-ol-0-0-3956],[@b20-ol-0-0-3956]). *CA9* is also a therapeutic target for metastasis ([@b21-ol-0-0-3956]). *CA2* and *CA9* were demonstrated to be overexpressed in endometrial adenocarcinoma, regulating the pH in the tumor microenvironment ([@b22-ol-0-0-3956]). Similarly, *CA2* was identified as a metastasis-associated gene in CRC in the present study. Proteomics analysis identified *CA2* as a potential biomarker, which exerted significant inhibitory effects on cell growth in CRC ([@b23-ol-0-0-3956]). *CA2* expression was also associated with lymph node metastasis in gastric cancer, and a previous study reported that its reduction may contribute to tumor metastasis ([@b24-ol-0-0-3956]). Therefore, *CA2* may also be used as a therapeutical target for metastasis.

*CEACAM7* is expressed in normal colon tissues, but is downregulated in CRC ([@b25-ol-0-0-3956]). By contrast, its expression is upregulated in liver metastases ([@b26-ol-0-0-3956]). *CEACAM6* also belongs to the CEACAM subgroup, which is mainly associated with the cell membrane. A previous study suggested that *CEACAM6* plays a role in tumor cell migration, adhesion and invasion, as well as the formation of distant metastases ([@b27-ol-0-0-3956]). In addition, the expression of *CEACAM6* in CRC is an independent prognostic factor ([@b28-ol-0-0-3956]). Furthermore, downregulation of *CEACAM7* in early-stage adenomas represents certain observable molecular events that may lead to CRC ([@b29-ol-0-0-3956]). In the present study, *CEACAM7* was also identified as a metastasis-associated gene.

*FCGBP* has been reported to be implicated in ulcerative colitis, which is a chronic inflammatory disease predisposing to CRC ([@b30-ol-0-0-3956],[@b31-ol-0-0-3956]). This gene may play a role in anti-inflammation and cell protection in tissues ([@b32-ol-0-0-3956]). The mutation of *FCGBP* has been previously identified in CRC ([@b33-ol-0-0-3956]), while it was also identified to be a DEG in metastatic CRC in the current study. Notably, in gallbladder adenocarcinoma, *FCGBP* functions as an important maker for clinical prognosis ([@b34-ol-0-0-3956]). Using the univariate Cox model and Kaplan-Meier survival curve, a correlation between *FCGBP* expression and overall survival in ovarian adenocarcinoma was observed ([@b35-ol-0-0-3956]). The survival curve of CRC patients with liver metastasis in the present study also detected an association of *FCGBP* with prognosis. Furthermore, *FCGBP* was significantly enriched in the function of cell adhesion. Metastasis is facilitated by the cell-cell interactions between the endothelium and tumor cells in distant tissues. Cell adhesion occurring in vasculature of specific organs is an essential step in cancer metastasis ([@b36-ol-0-0-3956]). Thus, we infer that *FCGBP* may exert an important role during metastasis in CRC by participating in cell adhesion.

In conclusion, using the metaDE package in R language, DEGs were screened in two sets of gene expression profiles, which may be able to distinguish the metastasis samples from the primary cancer samples. Candidate metastasis-associated genes identified by comparing with a third expression dataset were further subjected to survival analysis. Therefore, *CA2* has the potential to be used as a therapeutic target for metastatic CRC, while *FCGBP* may affect patients\' survival by participating in cell adhesion.
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![Plots of numbers of DEGs against FDR obtained from the metaDE analysis. DEGs, differentially expressed genes; FDR, false discovery rate.](ol-11-01-0568-g01){#f2-ol-0-0-3956}

![Hierarchical clustering of DEGs identified using metaDE analysis in primary and metastatic CRC samples. Values 0 and 1 at the top of the graph represent the primary and metastatic samples, respectively. Dataset 1 refers to the profiles of GSE14297, and database 2 refers to the profiles of GSE9355. Green indicates the downregulated genes, while red indicates the upregulated genes in metastatic samples. DEGs, differentially expressed genes; CRC, colorectal cancer.](ol-11-01-0568-g02){#f3-ol-0-0-3956}
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###### 

Enriched functions and pathways of upregulated genes in the GSE14927 and GSE40355 datasets.

  Category        Term                                                        Count   FDR
  --------------- ----------------------------------------------------------- ------- ----------------
  GOTERM_BP_FAT   GO:0009611 - response to wounding                             62      6.60×10^−35^
  GOTERM_BP_FAT   GO:0002526 - acute inflammatory response                      31      1.14×10^−28^
  GOTERM_BP_FAT   GO:0006954 - inflammatory response                            40      1.52×10^−21^
  GOTERM_BP_FAT   GO:0006952 - defense response                                 47      2.73×10^−17^
  GOTERM_BP_FAT   GO:0006956 - complement activation                            17      5.18×10^−16^
  GOTERM_CC_FAT   GO:0005615 - extracellular space                              72      3.85×10^−38^
  GOTERM_CC_FAT   GO:0005576 - extracellular region                           106       1.02×10^−32^
  GOTERM_CC_FAT   GO:0044421 - extracellular region part                        73      2.28×10^−29^
  GOTERM_CC_FAT   GO:0034364 - high-density lipoprotein particle                13      5.44×10^−13^
  GOTERM_CC_FAT   GO:0032994 - protein-lipid complex                            14      1.92×10^−12^
  GOTERM_MF_FAT   GO:0004866 - endopeptidase inhibitor activity                 25      1.14×10^−15^
  GOTERM_MF_FAT   GO:0030414 - peptidase inhibitor activity                     25      4.15×10^−15^
  GOTERM_MF_FAT   GO:0004857 - enzyme inhibitor activity                        30      4.14×10^−14^
  GOTERM_MF_FAT   GO:0004867 - serine-type endopeptidase inhibitor activity     18      2.68×10^−11^
  GOTERM_MF_FAT   GO:0030246 - carbohydrate binding                             26    1.05×10^−7^
  KEGG_PATHWAY    hsa04610: Complement and coagulation cascades                 31      1.22×10^−28^
  KEGG_PATHWAY    hsa00982: Drug metabolism                                     15    1.31×10^−7^
  KEGG_PATHWAY    hsa00980: Metabolism of xenobiotics by cytochrome P450        13    1.32×10^−5^
  KEGG_PATHWAY    hsa00830: Retinol metabolism                                  11    4.99×10^−4^

GO, gene oncology; BP, biological process; CC, cellular component; MF, molecule function; FDR, false discovery rate.

###### 

Enriched functions of downregulated genes in datasets of GSE14927 and GSE40355.

  Category        Term                                                       Count   FDR
  --------------- ---------------------------------------------------------- ------- ----------------
  GOTERM_BP_FAT   GO:0001944 - vasculature development                       17      3.30×10^−6^
  GOTERM_BP_FAT   GO:0007155 - cell adhesion                                 26      1.42×10^−5^
  GOTERM_BP_FAT   GO:0022610 - biological adhesion                           26      1.46×10^−5^
  GOTERM_BP_FAT   GO:0001568 - blood vessel development                      15      1.42×10^−4^
  GOTERM_BP_FAT   GO:0048514 - blood vessel morphogenesis                    13      1.31×10^−3^
  GOTERM_BP_FAT   GO:0042127 - regulation of cell proliferation              23      7.84×10^−3^
  GOTERM_CC_FAT   GO:0044421 - extracellular region part                     53        2.54×10^−22^
  GOTERM_CC_FAT   GO:0005576 - extracellular region                          72        1.22×10^−21^
  GOTERM_CC_FAT   GO:0031012 - extracellular matrix                          29        8.38×10^−15^
  GOTERM_CC_FAT   GO:0005578 - proteinaceous extracellular matrix            28        1.31×10^−14^
  GOTERM_CC_FAT   GO:0005615 - extracellular space                           31      8.12×10^−9^
  GOTERM_CC_FAT   GO:0044420 - extracellular matrix part                     11      3.75×10^−4^
  GOTERM_CC_FAT   GO:0030934 - anchoring collagen                              5     1.56×10^−3^
  GOTERM_CC_FAT   GO:0005581 - collagen                                        7     1.59×10^−3^
  GOTERM_MF_FAT   GO:0005201 - extracellular matrix structural constituent   11      1.11×10^−5^

GO, gene oncology; BP, biological process; CC, cellular component; MF, molecule function; FDR, false discovery rate.
